ArticleScientific reports2025
Discovery of a novel genogroup feline calicivirus through molecular evolution in group-housed cats in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Localized adaptive evolution in VP1 drives antigenic divergence of feline calicivirus despite high sequence conservation.Veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Feline calicivirus (FCV) is a highly infectious pathogen that causes upper respiratory tract disease (URTD), with a higher prevalence in group-housed cats compared to those raised individually. In this study, 15 FCV strains were isolated from group-housed cats exhibiting URTD symptoms in Changzhou, China, in 2024. Phylogenetic analysis based on the VP1 sequences revealed that 13 of 15 strains clustered within genogroup I (G I), while none belonged to genogroup II (G II). Notably, the remaining two strains grouped with several recently published Chinese isolates, forming an independent branch distinct from both G I and G II, proposed as genogroup III (G III). The VP1 proteins of the 13 G I strains exhibited specific residues 377N, 539A, and 557G, consistent with the established G I-specific markers (377N/S, 539A/P, and 557G). In contrast, G II strains typically retain 377 K, 539 V, and 557S. Interestingly, the G III strains displayed 377N, 539A (specific to G I) and 557S (specific to G II). Recombinant analysis found that co-circulating G I and G III resulted in a recombinant strain. Furthermore, neutralization tests demonstrated poor cross-neutralization between G I and G III strains. This study provides valuable insights for the development of effective vaccination strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.